Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The purchases involved 35,000 securities at a highest price per unit of 0.0132 and a lowest price per unit of 0.0132. The sales, on the other hand, amounted to 503,492 securities at a highest price per unit of 0.0142 and a lowest price per unit of 0.0141.
The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics' securities. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer.
The Form 8.5 (EPT/RI) disclosure was made on November 8, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.
Please note that this summary only includes information directly provided in the news and does not include any regulatory, contact, or general risk information.